BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Kelun-Biotech's Fourth Indication for ADC sac-TMT Accepted for Priority Review in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophob...

May 22, 2025 | News

Minghui Doses First Patient in Phase II Trial of PD-1xVEGF Bispecific and TROP-2 ADC Combo for Advanced NSCLC

Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, announced that ...

May 21, 2025 | News

Nordic Bioscience Launches nordicEndotrophin™ to Advance Risk Stratification and Monitoring in Fibrosis and Cancer

Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrop...

May 19, 2025 | News

Agilent and Ubix Therapeutics Join Forces to Advance Targeted Cancer Therapies in South Korea

Research focuses on targeted protein degradation and antibody-drug conjugate as promising modalities for developing next-generation cancer therapies ...

May 15, 2025 | News

Hyundai ADM Bio Withdraws IND for Penetrium™/Docetaxel and Pivots to Immunotherapy Combinations

Hyundai ADM Bio announced the voluntary withdrawal of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating Pene...

May 14, 2025 | News

EnGeneIC Doses First Patient in Phase I/IIa Trial for EGFR-Positive Solid Tumours at Mater Hospital, Sydney

First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North Sydney Recruitment to open this month at Frankston Hospital, ...

May 13, 2025 | News

Gene Solutions Validates K-TRACK™ ctDNA Test as Prognostic Biomarker

Gene Solutions, a biotechnology company dedicated to advancing precision oncology in Asia, is excited to announce the publication of a pioneering real-worl...

May 12, 2025 | News

Nutshell Therapeutics Receives FDA IND Clearance for First-in-Human Trial of NTS071 Targeting p53 Y220C Mutation

Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical ...

May 05, 2025 | News

InnoCare’s Zurletrectinib Granted Priority Review in China for NTRK Fusion-Positive Solid Tumors

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new genera...

May 05, 2025 | News

TAE Life Sciences and Ohio State Forge Landmark BNCT Partnership to Advance Next-Generation Boron-Based Cancer Therapies

TAE Life Sciences (TLS) announced the signing of a Letter of Intent to collaborate with The Ohio State University Comprehensive Cancer Center – ...

May 05, 2025 | News

Akeso’s Ivonescimab Outperforms Pembrolizumab in Phase III, Wins NMPA Approval for First-Line PD-L1-Positive NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has re...

April 28, 2025 | News

Innovent Biologics Secures NMPA Approval for Limertinib as First-Line Therapy for EGFR-Mutated NSCLC in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

April 28, 2025 | News

Gene Solutions and Element Biosciences Forge Multiomics Collaboration to Expand Access to Genetic Testing Across Asia and Beyond

Gene Solutions, a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company democratizing acc...

April 23, 2025 | News

GC Cell Secures Exclusive Rights to DAAN Biotherapeutics’ Tumor Antigen-Specific Antibody for CAR-T and CAR-NK Therapies

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusi...

April 22, 2025 | News

Stay Connected